Automate Your Wheel Strategy on SYK
With Tiblio's Option Bot, you can configure your own wheel strategy including SYK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SYK
- Rev/Share 65.6627
- Book/Share 58.6144
- PB 6.1558
- Debt/Equity 0.6628
- CurrentRatio 1.8931
- ROIC 0.0738
- MktCap 137986100671.0
- FreeCF/Share 11.1974
- PFCF 32.2172
- PE 42.5181
- Debt/Assets 0.3106
- DivYield 0.0094
- ROE 0.1504
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | SYK | TD Cowen | -- | Hold | -- | $387 | Jan. 27, 2026 |
| Upgrade | SYK | Raymond James | Market Perform | Outperform | -- | $418 | Jan. 6, 2026 |
| Upgrade | SYK | Citizens JMP | Market Perform | Mkt Outperform | -- | $440 | Dec. 19, 2025 |
| Initiation | SYK | Rothschild & Co Redburn | -- | Neutral | -- | $420 | Sept. 18, 2025 |
| Resumed | SYK | Citigroup | -- | Buy | -- | $450 | Feb. 26, 2025 |
| Initiation | SYK | Wolfe Research | -- | Outperform | -- | $405 | Sept. 10, 2024 |
News
SYK Stock Gains as Q4 Earnings & Sales Beat on Strong Mako Adoption
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
SYK shares rise after fourth-quarter EPS and sales top estimates, fueled by double-digit organic growth and strong adoption of its Mako platform.
Read More
SYK's Q4 Results Likely to Reflect Procedure Growth and Capital Demand
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Stryker's fourth-quarter results are expected to highlight resilient procedure volumes and strong capital demand, supported by product momentum and broad-based strength.
Read More
Here's Why Stryker (SYK) is a Strong Momentum Stock
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Gear Up for Stryker (SYK) Q4 Earnings: Wall Street Estimates for Key Metrics
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Stryker (SYK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Read More
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Neutral
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
HOLX vs. SYK: Which Medical Device Leader Is a Solid Bet Now?
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
Hologic and Stryker gear up for earnings with diagnostic wins, surgical growth and strategic moves shaping the medical device race.
Read More
NVST vs. SYK: Which Stock Is the Better Value Option?
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
Read More
NVST vs. SYK: Which Stock Should Value Investors Buy Now?
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Intuitive Surgical vs. Stryker: Which MedTech Stock Has More Upside?
Published: December 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Intuitive Surgical's robotics-first model, recurring revenue base, and margin leverage differentiate it from Stryker in terms of upside potential today.
Read More
Why Stryker (SYK) is a Top Growth Stock for the Long-Term
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
3 Healthcare Giants Just Raised Dividends—Here's Who Pays the Most
Published: December 16, 2025 by: MarketBeat
Sentiment: Positive
Major players in healthcare are increasing their commitments to return capital to shareholders, resulting in significantly higher dividends. Recent dividend announcements from major companies in the sector highlight evolving capital return strategies.
Read More
3 MedTech Stocks Poised to Gain in 2026 From the AI Boom
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
AI is reshaping MedTech, and Stryker, Tempus AI and GE HealthCare are emerging as key players leveraging AI across surgery, diagnostics and imaging.
Read More
Why Stryker (SYK) is a Top Momentum Stock for the Long-Term
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems?
Published: November 25, 2025 by: MarketBeat
Sentiment: Neutral
Over $500 million in insider stock sales have hit three high-profile companies this month—an unsettling signal that even top executives and major stakeholders may be questioning the sustainability of recent gains.
Read More
Compared to Estimates, Stryker (SYK) Q3 Earnings: A Look at Key Metrics
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
What Analyst Projections for Key Metrics Reveal About Stryker (SYK) Q3 Earnings
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Stryker (SYK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
Read More
Will SYK's Q3 Results Reflect MedSurg Strength & Rebound in Orthopaedics?
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.
Read More
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. SYK, NVDA, RMD and RL hold promise.
Read More
SNN or SYK: Which Is the Better Value Stock Right Now?
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.
Read More
Stryker Expands R&D Facility in India to Boost Medtech Innovation
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
SYK expands its Bangalore R&D hub to accelerate robotics, AI and digital health innovation while deepening ties with India's talent pool.
Read More
SNN vs. SYK: Which Stock Is the Better Value Option?
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Smith & Nephew (SNN) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
SYK Partners With Siemens Healthineers to Boost Stroke, Aneurysm Care
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Stryker teams with Siemens Healthineers to develop a robotic ecosystem aimed at advancing stroke and aneurysm care.
Read More
SNN or SYK: Which Is the Better Value Stock Right Now?
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Investing in the Age of Longevity: Silver Economy Stocks in Focus
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Read More
Stryker's Robotics and Global Gains Offset by Macro Concerns
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
SYK posted strong Q2 growth driven by Mako robotics and global demand, but inflation, FX and competitive pressures temper near-term upside.
Read More
Stryker Q2: Record Mako Installation And High Utilization
Published: August 19, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate a Hold rating on Stryker Corporation, with a fair value of $382 per share, despite recent strong quarterly results. Stryker's Mako installations and utilization remain robust, and upcoming Mako Spine and shoulder launches are on track to drive future growth. SYK management is focused on margin expansion through supply chain efficiencies, but cost synergies from past acquisitions remain under-realized.
Read More
Stryker: Strong Multi-Faceted Growth Continuing To Support The Shares
Published: August 19, 2025 by: Seeking Alpha
Sentiment: Positive
Stryker continues to outperform peers with strong revenue growth, margin expansion, and successful product innovation. Recent quarterly results beat expectations, driven by robust performance across the business and ongoing market share gains. Management remains focused on growth and margin optimization, with M&A and innovation — especially in robotics and neuromodulation — central to the strategy.
Read More
Stryker (SYK) Upgraded to Buy: What Does It Mean for the Stock?
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Stryker (SYK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
SNN vs. SYK: Which Stock Is the Better Value Option?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
Read More
About Stryker Corporation (SYK)
- IPO Date 1980-03-17
- Website https://www.stryker.com
- Industry Medical - Devices
- CEO Kevin A. Lobo
- Employees 53000